APOC3 dsRNA Compositions for Targeted Triglyceride Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for regulators of APOC3 expression to treat apolipoprotein C3-associated disorders such as hypertriglyceridemia, which are associated with elevated triglyceride levels and various diseases including cardiovascular disease, atherosclerosis, non-alcoholic fatty liver disease, and type 2 diabetes mellitus.

Innovation Solution

The use of double-stranded ribonucleic acid (dsRNA) agents to inhibit the expression of apolipoprotein C3 (APOC3) in cells by targeting specific RNA sequences, utilizing modified nucleotides and ligands to enhance efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If APOC3 expression is not regulated, then lipoprotein metabolism remains normal, but hypertriglyceridemia and associated diseases develop due to elevated triglyceride levels

Engineering Contradiction:

Improvetriglyceride level controlVSAvoidhypertriglyceridemia and associated diseases

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets the specific APOC3 mRNA sequence using dsRNA agents, isolating the pathological element (APOC3 overexpression) from the overall lipoprotein metabolism system. By designing dsRNA complementary to APOC3 mRNA, the invention selectively removes the harmful overexpression without disrupting other metabolic pathways.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the expression parameter of APOC3 from elevated to reduced levels through RNA interference. By introducing dsRNA agents that trigger RISC-mediated cleavage, the invention transforms the APOC3 expression state, thereby altering triglyceride metabolism from a pathological to a healthier state.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If dsRNA agents are used to inhibit APOC3 expression, then triglyceride levels are reduced, but off-target effects and immunogenicity may occur

Engineering Contradiction:

ImproveAPOC3 expression inhibitionVSAvoidoff-target effects and immunogenicity

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by designing dsRNA agents with specific sequence complementarity only to the APOC3 mRNA target region. The invention uses carefully selected nucleotide sequences that match APOC3 mRNA but not other transcripts, ensuring localized and specific inhibition while minimizing off-target effects throughout the genome.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent introduces the RISC complex as an intermediary between the dsRNA agent and the target mRNA. The dsRNA does not directly degrade mRNA but rather guides RISC to perform the cleavage, providing a controlled and specific mechanism that reduces immunogenicity compared to direct RNA degradation approaches.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If conventional therapies are used for hypertriglyceridemia, then treatment options are limited, but efficacy is insufficient for severe cases

Engineering Contradiction:

Improvetreatment optionsVSAvoidtreatment efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent replaces conventional mechanical/pharmacological therapies with a molecular-level intervention using RNA interference. Instead of using small molecule drugs that modulate enzyme activity, the invention uses dsRNA agents that directly silence the APOC3 gene at the RNA level, providing a more targeted and potentially more effective treatment mechanism.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The dsRNA agents effectively reduce APOC3 expression, potentially lowering triglyceride levels and mitigating associated diseases by interfering with APOC3's regulatory functions on lipolysis and VLDL synthesis.

Implementation Method 1

iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a gene encoding apolipoprotein C3 (APOC3)

Methodology Applied

Scientific EffectRNA interference (RNAi):

Data Source

PatentUS12522822B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

Publication Date: 2026.01.13 ALNYLAM PHARMACEUTICALS INC

AI summary

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.